- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02261415
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial (HeLiX)
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial: Tranexamic Acid (TXA) Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Liver Resection: A Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Purpose Compelling biological rationale and indirect evidence from other settings suggest that there is potential benefit to administering TXA to patients undergoing liver resection. A lack of consensus in the hepatobiliary community and lack of direct evidence in patients undergoing liver resection mandate a RCT.
Hypothesis To determine the impact of perioperative administration of TXA to patients undergoing liver resection on the need for blood transfusion and long-term survival.
Justification If TXA use in liver resection resulted in an important decrease in blood transfusions, clinical practice worldwide would be likely to change. Over 2000 patients in Canada undergo liver resection annually and could benefit from this simple, low-cost intervention. This intervention could easily be implemented in other countries, where many more patients undergo liver resection annually. Furthermore, TXA may be beneficial in other operative fields where bleeding is a major problem, including thoracic surgery, colorectal surgery, and many others.
Objectives
The primary outcome of the RCT will be:
1) Receipt of blood transfusion (% transfused): 7 days
The secondary outcomes of the RCT are:
- Intraoperative blood loss will be assessed by adding the net weight of sponges and fluid suction (minus irrigation and intraoperative bile or other fluids in suction/sponge)
- Total blood loss (postoperative day (POD)0 - POD7) will be assessed by Gross' formula, which uses the maximum postoperative decrease in the level of hemoglobin adjusted for the weight and height of the patient
- Number of packed red blood cells (PRBC) units transfused (POD0 - POD7)
- Postoperative incidence of symptomatic venous thromboembolic event confirmed with either computed tomography (CT) angiogram (for pulmonary embolism) or venous Doppler ultrasound (for deep venous thrombosis) (within 90 days of surgery)
- Postoperative complications (within 90 days of surgery) will be determined using the Clavien-Dindo classification
Recurrence free survival (within 5 years of surgery) will be determined by review of patient medical record every 6 months until 5 years post-surgery
a. Recurrence free survival is defined as the time from POD0 to the first event that is recurrent (local or distal) cancer or death (from any cause)
Overall survival (within 5 years of surgery) will be determined by review of patient medical record every 6 months until 5 years post-surgery
a. Overall survival is defined as the time from date of POD0 to death from any cause
- QOL will be determined by administering European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) -C30 and the QLQ- Liver Metastases Colorectal (LMC) 21 at baseline, 30 and 90 days following surgery
- Perioperative mortality will be recorded between POD0 and POD7
- Economic analysis will assess impact of TXA incorporation on health care resources and strategies for systematic utilization of TXA
Research Method This is a Phase III multicentre randomized controlled trial (RCT) to evaluate the impact of tranexamic acid (TXA) on perioperative blood transfusion in patients undergoing liver resection. The trial will conceal allocation, maximize possible blinding, independently assess the appropriateness of transfusion, use strategies to limit loss to follow-up and crossovers, and use a conservative stopping rule. Patients will be administered a single dose of study drug intravenously immediately after induction of anaesthesia, followed by infusion over eight hours.
Statistical Analysis Primary analysis will include only patients who underwent liver resection; patients who are randomized but do not receive liver resection (usually due to more advanced disease identified intraoperatively) will be excluded. A sensitivity analysis will be conducted whereby all randomized patients are included in the assessment of the primary outcome.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Hospital
-
-
British Colombia
-
Kelowna, British Colombia, Canada, V1Y 1T2
- Kelowna General Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2YR
- Queen Elizabeth II Health Sciences Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 8E7
- Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston General Health Research Institute
-
London, Ontario, Canada, N6A 5W9
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
Toronto, Ontario, Canada, M6R 1B5
- St. Joseph's Health Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- McGill University Health Centre
-
-
-
-
Minnesota
-
Rochester, Minnesota, United States
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient scheduled for open or laparoscopic liver surgery
- Age ≥18 years
- Cancer related diagnosis or indication (e.g. pre-cancer, suspicion of cancer, definite cancer)
Exclusion Criteria:
- Severe anemia (hemoglobin (Hgb) levels <90 g/l)
- Documented arterial or venous thrombosis at screening or in past three months (not including therapeutic portal vein embolization)
- Anticoagulants (other than low-molecular-weight heparin (LMWH) or heparin in prophylactic doses to prevent deep vein thrombosis), direct thrombin inhibitors or thrombolytic therapy administered or completed within last week
- Known disseminated intravascular coagulation
- Severe renal insufficiency (creatinine clearance (CrCl) <30 ml/min)
- History of seizure disorder
- Pregnant or lactating (a negative urine pregnancy test must be obtained for women of child bearing potential during the pretreatment evaluation)
- Acquired disturbance of colour vision
- Hypersensitivity to TXA or any of the ingredients
- Unable to receive blood products (i.e. difficulty with cross matching, refuses blood transfusion, or a past history of unexplained severe transfusion reaction)
- Previously enrolled in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tranexamic acid (TXA)
1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
|
1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
Other Names:
|
Placebo Comparator: Normal saline (0.9% sodium chloride)
1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
|
1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Receipt of blood transfusion (% transfused): 7 days
Time Frame: 7 days
|
Receipt of one or more RBC transfusions between Day 0 and Day 7
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative blood loss
Time Frame: 7 days
|
Intraoperative blood loss will be assessed by adding the net weight of sponges and fluid suction (minus irrigation and intraoperative bile or other fluids in suction/sponge)
|
7 days
|
Total blood loss
Time Frame: 7 days
|
Total blood loss (postoperative day (POD)0 - POD7) will be assessed by Gross' formula, which uses the maximum postoperative decrease in the level of hemoglobin adjusted for the weight and height of the patient
|
7 days
|
Number of packed red blood cells (PRBC) units transfused
Time Frame: 7 days
|
Number of packed red blood cells (PRBC) units transfused (POD0 - POD7)
|
7 days
|
Postoperative incidence of symptomatic venous thromboembolic event
Time Frame: 90 days
|
Postoperative incidence of symptomatic venous thromboembolic event confirmed with either computed tomography (CT) angiogram (for pulmonary embolism) or venous Doppler ultrasound (for deep venous thrombosis) (within 90 days of surgery)
|
90 days
|
Postoperative complications assessed using Clavien-Dindo Grading System
Time Frame: 90 days
|
Postoperative complications (within 90 days of surgery) will be determined using the Clavien-Dindo classification
|
90 days
|
Recurrence Free Survival (within 5 years of surgery)
Time Frame: 60 months
|
Disease recurrence is defined as the clinical presence of cancer that has either been confirmed by biopsy, has had treatment initiated, or is documented in the treating physician's notes.
Five year disease recurrence from day of surgery will be evaluated approximately every 6 months until 5 years via medical record review.
|
60 months
|
Overall Survival (within 5 years of surgery)
Time Frame: 60 months
|
Overall survival is defined as the time from date of surgery to death from any cause.
It will be determined by review of patient medical record every 6 months until 5 years post-surgery.
|
60 months
|
Quality of Life (QOL) Assessment using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30
Time Frame: Baseline, 30 days, 90 days
|
QOL will be determined by administering the EORTC QLQ-C30 at baseline, 30 and 90 days following surgery.
|
Baseline, 30 days, 90 days
|
Quality of Life (QOL) Assessment using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Liver Module (LM)C21 Questionnaire
Time Frame: Baseline, 30 days, 90 days
|
QOL will be determined by administering QLQ-LMC21 at baseline, 30 and 90 days following surgery.
|
Baseline, 30 days, 90 days
|
Perioperative mortality
Time Frame: 7 days
|
Perioperative mortality will be recorded between POD0 and POD7
|
7 days
|
Compare the cost of tranexamic acid (TXA) versus placebo on perioperative blood transfusion in patients undergoing liver resection
Time Frame: 90 days
|
Economic analysis will assess impact of TXA incorporation on health care resources and strategies for systematic utilization of TXA.
The analysis will be using data collected in the randomized controlled trial from a societal perspective.The output of the economic analysis is the incremental cost of TXA compared to placebo (control group).
|
90 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Paul Karanicolas, MD PhD, Sunnybrook Health Sciences Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 244-2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Tranexamic acid (TXA)
-
HaEmek Medical Center, IsraelWithdrawn
-
Rush University Medical CenterWithdrawnArthritis | Anemia | Total Knee Arthroplasty | Total Hip ArthroplastyUnited States
-
Boston Children's HospitalCompletedCraniosynostosisUnited States
-
NYU Langone HealthTerminated
-
Mansoura UniversityNot yet recruiting
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Cristina MartinezCompleted
-
Rush University Medical CenterCompletedBlood Loss After Primary Total Joint Arthroplasty | Need for Blood Transfusion After Total Joint ArthroplastyUnited States
-
University of Kansas Medical CenterCompletedSarcoma,Soft Tissue | Musculoskeletal CancerUnited States
-
NYU Langone HealthCompletedTibial Tubercle OsteotomyUnited States